You are here:
Archived: betaine anhydrous oral powder (Cystadane)
Advice
Following a re-submission
betaine anhydrous (Cystadane) is not recommended for use within NHS Scotland as adjunctive treatment of homocystinuria involving deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylene-tetrahydrofolate reductase (MTHFR) or cobalamin cofactor metabolism (cbl).
Clinical efficacy data for betaine anhydrous are limited.
The manufacturer did not present a sufficiently robust economic evaluation to gain acceptance by SMC.
Drug Details
| Drug Name: | betaine anhydrous oral powder (Cystadane) |
|---|---|
| SMC Drug ID: | 407/07 |
| Manufacturer: | Orphan Europe (UK) Ltd |
| Indication: | Adjunctive treatment of homocystinuria |
| BNF Category: | |
| Sub Category: | 9.8 Metabolic disorders |
| Submission Type: | Resubmission |
| Status: | Not Recommended |
| Date Advice Published: | 9 March 2009 |
Current Advice
| betaine anhydrous oral powder Cystadane | Resubmission | 9 August 2010 |
Archived Advice
| betaine anhydrous oral powder (Cystadane) | Full submission | 8 October 2007 |